CAMBRIDGE, Mass., April 26, 2012 /PRNewswire/ -- The Angiogenesis Foundation has opened registration for its 10th Annual M. Judah Folkman International Conference—Antiangiogenesis: New Frontiers in Therapeutic Development. The conference will take place on October 6-7, 2012 in Cambridge, MA, and attracts key opinion leaders from academia, industry and government to discuss the latest scientific and clinical findings on antiangiogenic cancer therapies.
The M. Judah Folkman conference draws an international roster of the world's leading clinicians and researchers in the field of angiogenesis-based cancer medicine to present the latest preclinical and clinical findings. In keeping with latest trends in the field, the 2012 conference will feature important presentations on regulators of angiogenesis, novel therapy targets in the angiogenic pathway, and promising biomarkers for predicting and measuring response to treatment. The conference will also feature talks by patient advocates who will relate their experiences with cancer and how they benefited from antiangiogenic treatments.
"The 10th anniversary of our M. Judah Folkman conference is a major milestone for the Angiogenesis Foundation," said Dr. William W. Li, the Foundation's President and Medical Director. "In the past 10 years, we have seen major advances in the antiangiogenic cancer therapy field, with approved drugs to treat most of the major tumor types, hundreds of ongoing clinical trials, and dozens of new therapy targets under investigation. This year's conference will highlight many of the new research trends in both the treatment and prevention of cancer using an antiangiogenic approach."
Early Bird Registration rates will end on Monday, April 30th. To review the topic and speaker agenda visit: http://www.angio.org/programs-cp-aa12.php.
As the world's leading non-profit organization dedicated to advancing the field of angiogenesis research, the Angiogenesis Foundation takes a multidisciplinary approach to its annual conference, bringing together experts and key stakeholders from basic research, life sciences industry, clinical investigation, and government to foster new collaborations and exchanges between faculty and attendees.
Due to limited space, early registration is encouraged. For additional information please contact, Michelle Sylvanowicz at (617) 401-2779.
SOURCE The Angiogenesis Foundation